Asia Pacific Point of Care TB and Drug-Resistant TB Testing Market (By Test: Molecular Diagnostics, Immunoassays; By End-use: Clinics and Hospitals, Diagnostic Laboratories) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Asia Pacific Point of Care TB and Drug-Resistant TB Testing Market Size and Forecast 2024 to 2033

The Asia Pacific point of care TB and drug-resistant TB testing market size was estimated at around USD 2.54 billion in 2023 and it is projected to hit around USD 4.83 billion by 2033, growing at a CAGR of 6.63% from 2024 to 2033. The Asia Pacific point-of-care (POC) tuberculosis (TB) and drug-resistant TB testing market is gaining significant momentum as TB remains a major public health concern in the region. The market's growth is driven by factors such as the high prevalence of TB, the increasing incidence of drug-resistant strains, advancements in diagnostic technologies, and government initiatives to combat the disease.

Asia Pacific Point of Care TB and Drug-Resistant TB Testing Market Size 2024 to 2033

Key Pointers

  • By Test, the immunoassays segment registered the maximum market share of 35% in 2023.
  • By Test, the culture-based tests segment is estimated to expand the fastest CAGR of 6.63% from 2024 to 2033.
  • By End Use, the clinics and hospitals segment generated the maximum market share of 49% in 2023.
  • By End Use, the diagnostic laboratories are expected to grow at the fastest CAGR of 7.53% during the forecast period.

What are the Growth Factors of Asia Pacific Point of Care TB and Drug-Resistant TB Testing Market?

The growth of the Asia Pacific point-of-care TB and drug-resistant TB testing market is primarily driven by the region's high burden of tuberculosis, including the increasing prevalence of multidrug-resistant TB. Governments and healthcare organizations are intensifying efforts to combat the spread of the disease through early detection and effective treatment strategies. Advancements in diagnostic technologies, such as rapid molecular assays and portable testing devices, are facilitating quicker and more accurate diagnosis at the point of care, reducing delays in treatment initiation. Additionally, growing awareness, increased funding for TB programs, and the expansion of healthcare infrastructure in emerging economies are further fueling market growth.

What are the Trends in Asia Pacific Point of Care TB and Drug-Resistant TB Testing Market?

  • Advancements in Diagnostic Technologies: Newer molecular diagnostics and rapid testing platforms are being developed for faster and more accurate detection of TB and drug-resistant strains at the point of care, significantly improving early diagnosis and treatment.
  • Rising Adoption of Portable Testing Devices: The adoption of portable, easy-to-use diagnostic devices is increasing in rural and resource-limited settings, helping expand access to testing in remote regions where healthcare infrastructure is less developed.
  • Increased Government Initiatives and Funding: Governments across the Asia Pacific are launching aggressive TB control programs, including subsidies for testing, drug-resistance monitoring, and public awareness campaigns aimed at combating the spread of tuberculosis.
  • Integration of Digital Health Solutions: There is a growing trend towards integrating digital health platforms with POC TB diagnostics, enabling better data collection, real-time monitoring, and effective patient follow-up, which enhances the overall management of the disease.

What are the Key Challenges Faced by Asia Pacific Point of Care TB and Drug-Resistant TB Testing Market?

  • High Cost of Advanced Diagnostic Technologies: Many advanced TB diagnostic tools, especially molecular tests for drug-resistant strains, are expensive and remain inaccessible to low-income populations and underfunded healthcare systems in the region.
  • Lack of Skilled Healthcare Personnel: A shortage of trained healthcare professionals to effectively use and interpret point-of-care TB testing technologies is a significant challenge, particularly in rural areas with limited healthcare infrastructure.
  • Limited Healthcare Infrastructure in Remote Areas: In many parts of the Asia Pacific, particularly in rural and underserved regions, inadequate healthcare infrastructure limits the widespread adoption of point-of-care testing, hindering timely diagnosis and treatment.
  • Diagnostic Accuracy in Resource-Limited Settings: Environmental conditions, such as temperature and humidity, can affect the performance of point-of-care diagnostic devices in rural areas, leading to concerns about the reliability and accuracy of test results.

Test Insights

In 2023, the immunoassays segment held a significant market share of 35%, largely due to the technology's proven effectiveness, user-friendliness, and versatility across various settings. Immunoassays, including enzyme-linked immunosorbent assays (ELISA) and lateral flow tests, are highly regarded in TB diagnostics for their sensitivity and specificity in identifying TB biomarkers and antibodies. The QuantiFERON-TB Gold test exemplifies this, offering reliable results for latent TB infections by assessing immune responses to specific TB proteins. Such accuracy is particularly vital in regions with high TB prevalence, like India and Indonesia, where timely detection is essential for effective disease management.

The culture-based tests segment is projected to experience the highest growth rate, with a CAGR of 6.63% during the forecast period. This growth is fueled by a growing demand for definitive diagnostic confirmation, advancements in culture technologies, and a deeper understanding of drug resistance. Culture-based tests, such as Löwenstein-Jensen cultures and liquid culture systems, are considered the gold standard for TB diagnosis due to their high sensitivity and ability to accurately identify drug resistance. Unlike molecular and immunoassay tests, culture methods confirm the presence of Mycobacterium tuberculosis and provide crucial drug susceptibility information necessary for managing drug-resistant TB.

End Use Insights

In 2023, the clinics and hospitals segment dominated the market, accounting for 49% of revenue. This leadership position stems from the critical role these healthcare facilities play in comprehensive patient management, the advancement of diagnostic technologies, and the growing need for effective TB and drug-resistant TB diagnostics. Clinics and hospitals are essential for TB diagnosis and treatment, offering a broad range of diagnostic tests and treatment options. They are equipped to perform complex procedures, such as molecular tests and culture-based assays, which are vital for accurate TB detection and drug resistance profiling. The high prevalence of TB in the Asia Pacific region, particularly in countries like India, China, and Indonesia, underscores the necessity for sophisticated diagnostic capabilities available in these settings.

Diagnostic laboratories are expected to grow at the fastest CAGR of 7.53% during the forecast period. The increasing complexity of TB cases, including multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains, demands specialized testing capabilities. Diagnostic laboratories are equipped to handle these intricate cases by offering comprehensive drug susceptibility testing and detailed microbiological analyses, which are crucial for effective treatment planning. The expansion of laboratory networks and the implementation of quality assurance programs have enhanced the capabilities of diagnostic laboratories, making them vital contributors to TB control. Additionally, investments in laboratory infrastructure and technology, along with government and international support, are further driving growth in this sector.

Country Insights

India Point of Care TB and Drug-Resistant TB Testing Market Trends
India's PoC TB and drug-resistant TB testing market is significantly influenced by the country's high TB burden, with 2.4 million cases reported in 2022, according to the Ministry of Health and Welfare. The nation faces challenges with multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains. To address these issues, the government has launched several initiatives, including the Pradhan Mantri TB Mukt Bharat Abhiyan, which has engaged over 100,000 Ni-kshay Mitras to support more than 1.1 million TB patients. Additionally, the Ni-kshay Poshan Yojana has allocated approximately USD 311 million to over 9.5 million TB patients since 2018. New initiatives like the Family Care Giver Model and Differentiated Care aim to improve treatment success rates and reduce mortality.

Market growth is further supported by strategic partnerships and new product introductions. For example, in October 2023, Serum Institute of India Pvt. Ltd. and Mylab Discovery Solutions Pvt. Ltd. launched a cost-effective PoC skin test for Latent Tuberculosis Infection (LTBI), priced 50% to 70% lower than existing tests. These collective efforts are expected to drive significant market expansion in the coming years.

China Point of Care TB and Drug-Resistant TB Testing Market Trends
The PoC TB and drug-resistant TB testing market in China is growing in response to the country's substantial TB burden and ongoing public health initiatives. As one of the countries with the highest TB incidence rates, China plays a significant role in the global TB caseload. According to WHO data, in 2022, eight countries accounted for over two-thirds of global TB cases, with China responsible for 7.1%. In response, the Chinese government has prioritized TB control in its national health strategies, including the adoption of advanced diagnostic technologies. Regulatory bodies like the National Medical Products Administration (NMPA) are facilitating the introduction of new diagnostic technologies by streamlining approval processes. These initiatives, along with increased healthcare investments, are propelling the growth of the PoC TB and drug-resistant TB testing market in China.

Japan Point of Care TB and Drug-Resistant TB Testing Market Trends
Japan's PoC TB and drug-resistant TB testing market is expanding due to the country's advanced healthcare system and proactive TB management strategies. The Japanese government has implemented a comprehensive TB control program that includes routine screenings and cutting-edge diagnostic technologies. The Ministry of Health, Labour, and Welfare is supporting the integration of innovative diagnostic tools, such as rapid molecular assays, to enhance TB detection and management. In April 2024, the health ministry announced the establishment of a new expert body by April 2025 to prepare for future infectious disease crises. Additionally, strategic initiatives by key market players are driving growth; for instance, in April 2023, QIAGEN introduced its QIAstat-Dx syndromic testing solution in Japan, featuring a SARS-CoV-2 Respiratory Panel capable of detecting over 20 pathogens from a single patient sample. This highlights the country’s commitment to integrating innovative diagnostics into its healthcare framework.

Recent Developments

  • In July 2023, EMPE Diagnostics introduced the mfloDx MDR-TB rapid test kit, which offers a fast, affordable, and accurate means of detecting Mycobacterium tuberculosis and its genotypic resistance. This kit has received approval from the CDSCO and is currently undergoing clinical trials in several other countries.
  • In March 2022, Thermo Fisher Scientific Inc. launched the SeqStudio Flex Series Genetic Analyzer, a state-of-the-art tool aimed at enhancing research and development in infectious disease detection. This innovative analyzer significantly boosts the company’s product offerings by providing advanced capabilities for detailed genomic analysis.
  • In February 2022, QIAGEN announced that its fourth-generation QuantiFERON tuberculosis (TB) testing solution, QuantiFERON-TB Gold Plus (QFT-Plus), received approval from China’s National Medical Products Administration (NMPA). This approval positions QFT-Plus as the latest gold standard for TB detection in China.

Who are the Top Manufactures in Asia Pacific Point of Care TB and Drug-Resistant TB Testing Market?

  • Cepheid (Danaher Corporation)
  • Molbio Diagnostics
  • Abbott Laboratories
  • BD (Becton, Dickinson and Company)
  • Roche Diagnostics
  • Qiagen
  • Lucira Health
  • BioMérieux
  • Thermo Fisher Scientific
  • Fujifilm (Fujifilm Healthcare)
  • MedMira
  • SD Biosensor
  • Trivitron Healthcare

Asia Pacific Point of Care TB and Drug-Resistant TB Testing Market Segmentation:

By Test

  • Molecular Diagnostics
  • Immunoassays
  • Culture-based Tests
  • Serological Tests
  • Others

By End Use

  • Clinics & Hospitals
  • Diagnostic Laboratories
  • Others

By Region

  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of APAC

Frequently Asked Questions

The Asia Pacific point of care TB and drug-resistant TB testing market size was reached at USD 2.54 billion in 2023 and it is projected to hit around USD 4.83 billion by 2033.

The Asia Pacific point of care TB and drug-resistant TB testing market is growing at a compound annual growth rate (CAGR) of 6.63% from 2024 to 2033.

The driving factors of the Asia Pacific point of care TB and drug-resistant TB testing market include the high prevalence of tuberculosis, increasing incidence of drug-resistant strains, advancements in diagnostic technologies, government initiatives for disease control, and the growing demand for rapid and accurate testing solutions in healthcare settings.

The leading companies operating in the Asia Pacific point of care TB and drug-resistant TB testing market are Cepheid (Danaher Corporation); Molbio Diagnostics; Abbott Laboratories; BD (Becton, Dickinson and Company); Roche Diagnostics; Qiagen; Lucira Health; BioMérieux; Thermo Fisher Scientific; Fujifilm (Fujifilm Healthcare); MedMira; SD Biosensor and Trivitron Healthcare.

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers